NKX3.1 haploinsufficiency is prognostic for prostate cancer relapse following surgery or image-guided radiotherapy

Clinical Cancer Research

Volumn 18, Issue 1, 2012, Pages 308-316

  Locke, Jennifer A ^a,b   Zafarana, Gaetano ^a,b   Ishkanian, Adrian S ^a,b   Milosevic, Michael ^a,b   Thoms, John ^a,b   Have, Cherry L ^a   Malloff, Chad A ^d   Lam, Wan L ^d   Squire, Jeremy A ^c   Pintilie, Melania ^a,b   Sykes, Jenna ^b   Ramnarine, Varune Rohan ^a,b   Meng, Alice ^a,b   Ahmed, Omer ^a,b   Jurisica, Igor ^a,b   Van Der Kwast, Theo ^a,b   Bristow, Robert G ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c QUEEN S UNIVERSITY   (Canada)

^d BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROSTATE STEM CELL ANTIGEN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NKX3.1; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CANCER RELAPSE; CANCER SURGERY; CELL RENEWAL; COHORT ANALYSIS; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA DAMAGE; GENE; GENE FUNCTION; GENETIC ASSOCIATION; GENOMIC INSTABILITY; HAPLOINSUFFICIENCY; HUMAN; HUMAN TISSUE; IMAGE GUIDED RADIOTHERAPY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; NEEDLE BIOPSY; NKX3.1 GENE; ONCOGENE C MYC; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; PSCA GENE; RADIATION DOSE; RADIOSENSITIVITY; RECURRENCE FREE SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

BLOTTING, WESTERN; COMBINED MODALITY THERAPY; COMPARATIVE GENOMIC HYBRIDIZATION; FOLLOW-UP STUDIES; HAPLOINSUFFICIENCY; HOMEODOMAIN PROTEINS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIATION TOLERANCE; RADIOTHERAPY, IMAGE-GUIDED; SURVIVAL RATE; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 84855454847     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2147     Document Type: Article

References (34)

1. Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 2010;8:162-200.
2. Nichol AM, Warde P, Bristow RG. Optimal treatment of intermediaterisk prostate carcinoma with radiotherapy: clinical and translational issues. Cancer 2005;104:891-905. (Pubitemid 41170215)
3. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Renshaw AA, Tomaszewski JE, et al. Optimizing patient selection for dose escalation techniques using the prostate-specific antigen level, biopsy gleason score, and clinical T-stage. Int J Radiat Oncol Biol Phys 1999;45:1227-33.
4. Ishkanian AS, Mallof CA, Ho J, Meng A, Albert M, Syed A, et al. Highresolution array CGH identifies novel regions of genomic alteration in intermediate-risk prostate cancer. Prostate 2009;69:1091-100.
5. Ishkanian AS, Zafarana G, Thoms J, Bristow RG. Array CGH as a potential predictor of radiocurability in intermediate risk prostate cancer. Acta Oncol 2010;49:888-94.
6. Jenkins RB, Qian J, Lieber MM, Bostwick DG. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 1997;57:524-31. (Pubitemid 27081674)
7. Kim JH, Dhanasekaran SM, Mehra R, Tomlins SA, Gu W, Yu J, et al. Integrative analysis of genomic aberrations associated with prostate cancer progression. Cancer Res 2007;67:8229-39. (Pubitemid 47395160)
8. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943-7. (Pubitemid 27148818)
9. Hawksworth D, Ravindranath L, Chen Y, Furusato B, Sesterhenn IA, McLeod DG, et al. Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence. Prostate Cancer Prostatic Dis 2010;13:311-5.
10. Wolfer A, Ramaswamy S. Prognostic signatures, cancer metastasis and MYC. Cell Cycle 2010;9:3639.
11. van Duin M, van Marion R, Vissers K, Watson JE, van Weerden WM, Schroder FH, et al. High-resolution array comparative genomic hybridization of chromosome arm 8q: evaluation of genetic progression markers for prostate cancer. Genes Chromosomes Cancer 2005;44:438-49. (Pubitemid 41476795)
12. Prochownik EV. c-Myc: linking transformation and genomic instability. Curr Mol Med 2008;8:446-58.
13. Luoto KR, Meng AX, Wasylishen AR, Zhao H, Coackley CL, Penn LZ, et al. Tumor cell kill by c-MYC depletion: role of MYC-regulated genes that control DNA double-strand break repair. Cancer Res 2010;70: 8748-59.
14. Wang X, Kruithof-de Julio M, Economides KD, Walker D, Yu H, Halili MV, et al. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 2009;461:495-500.
15. Bowen C, Bubendorf L, Voeller HJ, Slack R, Willi N, Sauter G, et al. Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res 2000;60:6111-5.
16. Bowen C, Gelmann EP. NKX3.1 activates cellular response to DNA damage. Cancer Res 2010;70:3089-97.
17. Bowen C, Stuart A, Ju JH, Tuan J, Blonder J, Conrads TP, et al. NKX3.1 homeodomain protein binds to topoisomerase I and enhances its activity. Cancer Res 2007;67:455-64. (Pubitemid 46192181)
18. Iwata T, Schultz D, Hicks J, Hubbard GK, Mutton LN, Lotan TL, et al. MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells. PLoS One 2010;5: e9427.
19. Zhao Z, Ma W, Zeng G, Qi D. PSCA mRNA expression in preoperatively negative prostate biopsies predicts incidental prostate cancer in patients undergoing transurethral resection of the prostate for benign prostatic hyperplasia. J Surg Oncol 2011;104: 672-8.
20. Bae KM, Su Z, Frye C, McClellan S, Allan RW, Andrejewski JT, et al. Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells. J Urol 2010;183:2045-53.
21. Zafarana G, Bristow RG. Tumor senescence and radioresistant tumorinitiating cells (TICs): let sleeping dogs lie! Breast Cancer Res 2010;12:111.
22. Diehn M, Cho RW, Lobo NA, Kalishy T, Dorie MJ, Kulp AN, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009;458:780-3.
23. Khojasteh M, Lam WL, Ward RK, MacAulay C. Astepwise framework for the normalization of array CGH data. BMC Bioinformatics 2005;6:274.
24. Shah SP, Xuan X, DeLeeuw RJ, Khojasteh M, Lam WL, Ng R, et al. Integrating copy number polymorphisms into arrayCGHanalysis using a robust HMM. Bioinformatics 2006;22:e431-9. (Pubitemid 44288313)
25. Chi B, deLeeuw RJ, Coe BP, Ng RT, MacAulay C, Lam WL. MDSeeGH: a platform for integrative analysis of multi-dimensional genomic data. BMC Bioinformatics 2008;9:243.
26. Chi B, DeLeeuw RJ, Coe BP, MacAulay C, Lam WL. SeeGH-a software tool for visualization of whole genome array comparative genomic hybridization data. BMC Bioinformatics 2004;5:13.
27. Bromfield GP, Meng A, Warde P, Bristow RG. Cell death in irradiated prostate epithelial cells: role of apoptotic and clonogenic cell kill. Prostate Cancer Prostatic Dis 2003;6:73-85. (Pubitemid 36432625)
28. DeWeese TL, Shipman JM, Dillehay LE, Nelson WG. Sensitivity of human prostatic carcinoma cell lines to low dose rate radiation exposure. J Urol 1998;159:591-8. (Pubitemid 28049287)
29. Roach M 3rd, Weinberg V, Nash M, Sandler HM, McLaughlin PW, Kattan MW. Defining high risk prostate cancer with risk groups and nomograms: implications for designing clinical trials. J Urol 2006;176: S16-20. (Pubitemid 44754980)
30. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11-22.
31. Maitland NJ, Collins AT. Prostate cancer stem cells: a new target for therapy. J Clin Oncol 2008;26:2862-70.
32. Ornstein DK, Cinquanta M, Weiler S, Duray PH, Emmert-Buck MR, Vocke CD, et al. Expression studies and mutational analysis of the androgen regulated homeobox gene NKX3.1 in benign and malignant prostate epithelium. J Urol 2001;165:1329-34. (Pubitemid 32210285)
33. Voeller HJ, Augustus M, Madike V, Bova GS, Carter KC, Gelmann EP. Coding region of NKX3.1, a prostate-specific homeobox gene on 8p21, is not mutated in human prostate cancers. Cancer Res 1997;57:4455-9. (Pubitemid 27441043)
34. Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, et al. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Cancer 2003;98:2344-50. (Pubitemid 37466649)